Inhibition of the innate immune system to disrupt “Don’t Eat Me” signals between tumor and macrophages is a rapidly growing area of drug development. LILRB1 and LILRB2 are two such immunomodulatory receptors but targeting them poses the challenges of avoiding ten highly homologous LILR family members that are also expressed on myeloid cells.  This presentation provides a rational and successful approach for overcoming these challenges utilizing a fully human, highly diverse antibody phage display library. It will also cover the next stages of antibody discovery and development, reviewing the in vitro and in vivo characterization required to go from antibody discovery to clinical candidate.

Monoclonal antibody discovery has been a foundational innovation that continues to drive novel antibody therapeutics in research areas, including cancer, autoimmune disease, and infectious disease. As the demands and requirements for new antibodies continue to evolve, especially around safety, efficacy, and functional characterization, more powerful screening technologies are critical to antibody discovery and therapeutic development success. Unlike hybridoma and display technologies that can limit antibody diversity, have low campaign success, and require months to perform, the Beacon® optofluidic technology enables rapid selection of lead candidates by serial function-first screening of single B cells to increase success rates and shorten antibody discovery timelines to days.

In this presentation, Vincent Pai and Dr. Yu Liang will first highlight Bruker Cellular Analysis’ full Beacon antibody discovery suite for screening primary plasma cells and memory B cells, including the newest ability to discover antibody hits based on relative binding affinity, and share how customers can leverage optofluidic technology to rapidly discover high value monoclonal antibodies with the highest chances of success and fastest turnaround times.

They will then highlight how GenScript uses the Beacon optofluidic system for initial single B cell screening, followed by the state-of-the-art ProSpeed expression system for rapid re-expression and enabling world-class antibody characterization. Genscript’s ProSpeed™ single B cell screening service transforms lead characterization, including deep functional antibody profiling and enhanced B cell receptor sequence recovery, making it faster and more cost effective than traditional plasmid-based expression systems.